{
    "clinical_study": {
        "@rank": "89264", 
        "brief_summary": {
            "textblock": "To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of\n      aerosol pentamidine versus placebo when used as a prophylactic agent in patients who have\n      recovered from their first episode of AIDS-associated Pneumocystis carinii pneumonia (PCP)."
        }, 
        "brief_title": "A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT). If AZT is started during the study, patients must have received =\n             or > 15 days of aerosol pentamidine before beginning AZT.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT). If AZT began prior to study entry, patients must have received = or\n             > 15 days of AZT before beginning aerosol pentamidine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those with either of the following AIDS-defining O.I.'s prior to entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Transfusion dependent (requiring blood transfusion more than once per month). The\n             last transfusion cannot have been given within 7 days of study entry.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Uncontrolled asthma.\n\n          -  Active therapy for tuberculosis.\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those with either of the following AIDS-defining O.I.'s prior to entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Transfusion dependent (requiring blood transfusion more than once per month). The\n             last transfusion cannot have been given within 7 days of study entry.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Uncontrolled asthma.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Antiretroviral agents other than zidovudine (AZT).\n\n          -  Immunomodulating agents.\n\n          -  Corticosteroids.\n\n        Active therapy for tuberculosis.\n\n        Patients must:\n\n          -  Have AIDS and recovered from their first episode of Pneumocystis carinii pneumonia\n             (PCP).\n\n          -  Be at least 2 weeks and no more than 24 weeks status post therapy for acute PCP.\n\n          -  Have positive antibody to HIV by a Government-approved ELISA test kit, or confirmed\n             Western blot test.\n\n          -  Adequate pulmonary function (vital capacity = or > 80 percent of predicted; forced\n             expiratory volume (FEV), 1 s = or > 65 percent of total FEV; and corrected pulmonary\n             diffusion capacity > 60 percent of predicted).\n\n          -  Free of acute medical problems.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002053", 
            "org_study_id": "022B", 
            "secondary_id": "87-72"
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentamidine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14603"
                }, 
                "name": "Fisons Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Montaner JS, et al. Aerosolized pentamidine for the secondary prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a report from the Canadian cooperative trial. Int Conf AIDS. 1989 Jun 4-9;5:295 (abstract no TBP54)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002053"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fisons", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1989"
    }, 
    "geocoordinates": {
        "Fisons Corp": "43.161 -77.611"
    }
}